Acer Medical (6857) H1 2026 earnings summary

Executive summary

• Revenue for the first half of 115 increased to $40,536 thousand, up from $30,121 thousand year-over-year, driven by both smart healthcare and health product segments.

• Net loss narrowed to $9,152 thousand from $15,144 thousand year-over-year, reflecting improved gross margin and higher revenue.

• Gross margin improved to 67% from 61% year-over-year, indicating better cost control and product mix.

Financial highlights

• Operating expenses rose to $37,469 thousand from $34,861 thousand year-over-year, mainly due to increased R&D and administrative costs.

• Cash and cash equivalents at period end were $153,770 thousand, down from $182,274 thousand a year earlier.

• Total assets decreased to $191,020 thousand from $209,496 thousand year-over-year.

• Equity declined to $155,772 thousand from $179,447 thousand year-over-year, reflecting accumulated losses.

• Basic and diluted loss per share improved to ($0.60) from ($0.99) year-over-year.

Outlook and guidance

• The company continues to focus on AI and big data analytics for smart healthcare, expanding product adoption in medical and international markets.

• No early adoption of new IFRS standards is planned; ongoing evaluation of future accounting changes.